Keybanc analyst Austin Wurschmidt maintains Ventas (NYSE:VTR) with a Overweight and lowers the price target from $56 to $55.
Teva Highlights Long-Term Data From Chorea Associated-Huntington’s Treatment
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced results from the ARC-HD trial, an approximately 3-year open-label study evaluating the safety and tolerability…